Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2 | Zendy

Scott R. Plotkin | Zendy; Anat StemmerRachamimov | Zendy; Fred G. Barker | Zendy; Chris Halpin | Zendy; Timothy P. Padera | Zendy; A. W. R. TYRRELL | Zendy; A. Gregory Sorensen | Zendy; Rakesh K. Jain | Zendy; Emmanuelle di Tomaso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Author(s) -

Scott R. Plotkin,

Anat StemmerRachamimov,

Fred G. Barker,

Chris Halpin,

Timothy P. Padera,

A. W. R. TYRRELL,

A. Gregory Sorensen,

Rakesh K. Jain,

Emmanuelle di Tomaso

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0902579

Subject(s) - medicine , neurofibromatosis type 2 , bevacizumab , neurofibromatosis , hearing loss , acoustic neuroma , vestibular system , schwannoma , vascular endothelial growth factor , surgery , oncology , pathology , chemotherapy , radiology , audiology , vegf receptors

Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research